Skip to main content

Advertisement

SpringerLink
Log in

Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Patients with advanced unresectable hilar cholangiocarcinoma have poor prognosis, and the survival is usually short. Herein, we report a 9-year survival case of unresectable hilar cholangiocarcinoma treated with chemoradiotherapy. A 64-year-old male patient presented with hilar cholangiocarcinoma. The tumor was located in the right hepatic duct, and it extended from the bifurcation of the anterior and posterior branches to the periphery. In the left side, the tumor extended from the umbilical portion to B2 and B3. However, there was no distant metastasis. The patient was then diagnosed with locally advanced, unresectable hilar cholangiocarcinoma and was treated with chemoradiotherapy. He received a total dose of 60 Gy in 30 daily fractions via intensity-modulated radiation therapy. In addition, he received gemcitabine chemotherapy for 5 years. There has been neither re-elevation of carbohydrate antigen 19-9 levels nor tumor relapse for 5 years during chemotherapy. Therefore, gemcitabine treatment was discontinued. However, the patient experienced tumor relapse 3 years after the last chemotherapy. Hence, chemotherapy with gemcitabine and cisplatin was initiated. At present, 1 year has passed after treatment for recurrence, and the patient has survived for 9 years since the initial treatment. Herein, we report a rare case of long-term survival with chemoradiotherapy in locally advanced unresectable hilar cholangiocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Igami T, Nishio T, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the ‘‘new era’’: the Nagoya experience. J Hepatobiliary Pancreat Surg 17:449–454

    Article  Google Scholar 

  2. Miyazaki M, Kimura F, Shimizu H et al (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 17:470–475

    Article  Google Scholar 

  3. Nuzzo G, Giuliante F, Ardito F et al (2012) Improvements in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147:26–34

    Article  Google Scholar 

  4. Matsuo K, Rocha FG, Ito K et al (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215:343–355

    Article  Google Scholar 

  5. Ratti F, Cipriani F, Piozzi G et al (2015) Comparative analysis of left- versus right-sided resection in Klatskin tumor surgery: can lesion side be considered a prognostic factor? J Gastrointest Surg 19:1324–1333

    Article  Google Scholar 

  6. Burke EC, Jarnagin WR, Hochwald SN et al (1998) Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228:385–394

    Article  CAS  Google Scholar 

  7. Ito F, Agni R, Rettammel RJ et al (2008) Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 248:73–79

    Article  Google Scholar 

  8. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

    Article  CAS  Google Scholar 

  9. Park J, Kim MH, Kim KP et al (2009) Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298–305

    Article  CAS  Google Scholar 

  10. Li H, Zhang ZY, Zhou ZQ et al (2016) Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 7:26888–26897

    Article  Google Scholar 

  11. Engineer R, Mehta S, Kalyani N et al (2017) High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience. J Gastrointest Oncol 8:180–186

    Article  Google Scholar 

  12. Chan SY, Poon RT, Ng KK et al (2005) Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. World J Gastroenterol 11:3161–3164

    Article  Google Scholar 

  13. Becker G, Momm F, Schwacha H et al (2005) Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report. World J Gastroenterol 11:4923–4926

    Article  Google Scholar 

  14. Kaido T, Imamura M (2005) Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology 52:725–727

    PubMed  Google Scholar 

  15. Ruys AT, van Haelst S, Busch OR et al (2012) Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg 36:2179–2186

    Article  Google Scholar 

  16. Mansour JC, Aloia TA, Crane CH et al (2015) Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17:691–699

    Article  Google Scholar 

  17. Gaspersz MP, Buettner S, van Vugt JLA et al (2017) Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford) 19:966–971

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Nara Medical University, 840 Shijo-cho Kashihara-shi, Nara, 634-8522, Japan

    Takeshi Sakata, Takahiro Yoshikawa, Takeo Nomi, Yasuko Matsuo, Naoki Kamitani, Daisuke Hokuto & Masayuki Sho

Authors
  1. Takeshi Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takahiro Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Nomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuko Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Kamitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Hokuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masayuki Sho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Yoshikawa.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakata, T., Yoshikawa, T., Nomi, T. et al. Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case. Int Canc Conf J 10, 41–45 (2021). https://doi.org/10.1007/s13691-020-00445-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-020-00445-z

Keywords

Search

Navigation